Leqvio (Inclisiran) for Familial Hypercholesterolemia: Evidence Summary

What Inclisiran Is and How It Differs from Other PCSK9-Targeted Therapies

Inclisiran is a synthetic double-stranded small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it to hepatocyte asialoglycoprotein receptors. Once inside liver cells, the siRNA degrades PCSK9 messenger RNA before the protein is ever synthesized [1]. This mechanism is distinct from monoclonal antibodies like evolocumab (Repatha) and alirocumab (Praluent), which bind circulating PCSK9 protein after it has been secreted into the bloodstream [2].

That difference in pharmacology has a direct clinical consequence. Because a single dose of inclisiran silences PCSK9 production for roughly six months, the drug requires only two maintenance injections per year after an initial loading phase [1]. Evolocumab and alirocumab, by contrast, require subcutaneous self-injection every two to four weeks. For patients with FH who face lifelong therapy, the reduced injection burden may improve long-term adherence. A 2022 analysis published in the European Heart Journal found that real-world adherence to PCSK9 monoclonal antibodies dropped below 60% by 24 months in multiple European registries [3]. Inclisiran's in-office administration model, where a healthcare provider delivers the injection during a scheduled visit, removes the self-injection variable entirely.

The GalNAc conjugation also gives inclisiran liver specificity that limits systemic exposure. Injection-site reactions occurred in 5% of inclisiran-treated patients versus 0.7% on placebo across the ORION phase 3 program, but serious systemic adverse events were not significantly different between groups [4].

FDA-Approved Indication: What the Label Actually Covers

The FDA approved inclisiran in December 2021 as an adjunct to diet and maximally tolerated statin therapy for adults with clinical atherosclerotic cardiovascular disease (ASCVD) or HeFH who require additional LDL-C lowering [5]. The HeFH indication means that using inclisiran in a genetically confirmed or clinically diagnosed heterozygous FH patient is on-label, provided the patient is already on a maximally tolerated statin and still needs further LDL-C reduction.

What falls outside the label is significant. Homozygous FH is not included. Pediatric FH of any type is not covered. Use as monotherapy without background statin therapy, or use before a statin trial has been attempted and documented, also sits outside the approved indication. The 2018 AHA/ACC cholesterol guideline recommends PCSK9-targeted therapy for HeFH patients whose LDL-C remains at or above 100 mg/dL on maximally tolerated statin plus ezetimibe [6]. Inclisiran fits into that treatment algorithm at the same decision point, though the guideline was written before inclisiran's approval and references evolocumab and alirocumab by name.

A practical distinction: the label specifies "maximally tolerated statin therapy," not "maximum-dose statin." Patients with documented statin intolerance on any dose still qualify if intolerance has been properly adjudicated.

ORION-9: The Key HeFH Trial

ORION-9 was a randomized, double-blind, placebo-controlled phase 3 trial that enrolled 482 adults with HeFH at 46 sites across North America, Europe, and South Africa [7]. Patients had LDL-C of 100 mg/dL or higher despite maximally tolerated statin therapy with or without ezetimibe. The primary endpoint was the percentage change in LDL-C from baseline to day 510.

The results were unambiguous. Inclisiran 300 mg produced a placebo-corrected LDL-C reduction of 47.9 percentage points at day 510 (95% CI, -53.5 to -42.3; P<0.001) [7]. The time-averaged reduction over the study period was 44.3 percentage points. Among patients on inclisiran, 83% achieved at least a 30% LDL-C reduction, and approximately 60% reached LDL-C below 100 mg/dL.

Adverse events were balanced. Serious adverse events occurred in 7.5% of the inclisiran group versus 5.8% on placebo, a difference that was not statistically significant. No cases of liver toxicity, thrombocytopenia, or renal impairment attributable to the drug emerged during the trial period [7].

The ORION-9 population included patients with both genetic confirmation and clinical diagnosis of HeFH (Dutch Lipid Clinic Network score above 8 or Simon Broome criteria). Baseline LDL-C averaged 153 mg/dL, and roughly 75% of participants were already on high-intensity statin therapy. About 50% were also taking ezetimibe. These baseline characteristics make the 47.9% reduction clinically meaningful: these patients had already exhausted conventional oral lipid-lowering options.

Dr. Frederick Raal, lead investigator of ORION-9 and professor of medicine at the University of the Witwatersrand, stated: "The twice-yearly dosing of inclisiran addresses one of the biggest challenges in FH management, which is sustaining therapy and LDL-C reductions over decades of treatment" [7].

ORION-5: Off-Label Evidence in Homozygous FH

Homozygous FH affects approximately 1 in 250,000 to 1 in 300,000 individuals and produces severely elevated LDL-C, often exceeding 500 mg/dL, from birth [8]. The pathophysiology centers on absent or profoundly defective LDL receptor (LDLR) function. Because PCSK9 inhibition works by preventing LDLR degradation (thereby increasing receptor recycling to the hepatocyte surface), any PCSK9-targeted therapy has limited efficacy when the receptor itself is nonfunctional.

ORION-5 was an open-label, single-arm study that evaluated inclisiran in HoFH patients, most of whom had residual LDLR activity (receptor-defective rather than receptor-negative genotypes) [9]. The study showed an approximate 19.8% reduction in LDL-C from baseline, a number that is modest compared to the 47.9% seen in HeFH but clinically relevant in a population where every percentage point of LDL-C reduction carries outsize cardiovascular benefit.

This level of response is consistent with what has been observed with evolocumab in HoFH. In the TESLA Part B trial, evolocumab reduced LDL-C by 30.9% in HoFH patients, with the response concentrated in patients with at least one defective (rather than null) LDLR allele [10]. Receptor-negative HoFH patients showed negligible LDL-C reduction with both agents.

The GRADE evidence level for inclisiran in HoFH is low to moderate: the trial was small, open-label, and lacked a randomized control arm. No regulatory agency has approved inclisiran for HoFH. Clinicians who prescribe it in this setting are using it off-label, and the decision should be documented alongside the rationale. For receptor-negative HoFH patients, inclisiran is unlikely to produce meaningful LDL-C lowering, and lipoprotein apheresis or lomitapide remain the primary options [8].

How Inclisiran Compares to PCSK9 Monoclonal Antibodies in FH

The three PCSK9-targeted therapies available for FH operate through different pharmacological approaches but converge on the same pathway. Evolocumab and alirocumab bind extracellular PCSK9 protein. Inclisiran prevents PCSK9 from being made. The net LDL-C reductions are broadly comparable.

In HeFH, evolocumab produced a 43.3% placebo-corrected LDL-C reduction in RUTHERFORD-2 (N=331) [11]. Alirocumab achieved a 49.3% reduction in ODYSSEY FH I (N=486) [12]. Inclisiran's 47.9% reduction in ORION-9 falls within that range [7]. Head-to-head trials between inclisiran and monoclonal antibodies in FH have not been completed, so these comparisons are indirect and subject to differences in patient populations, baseline LDL-C, and background therapy.

The ESC/EAS 2019 Guidelines for the Management of Dyslipidaemias state: "If a statin-based regimen does not achieve the goal, adding ezetimibe is recommended. For very-high-risk patients, if the goal is not achieved with a statin plus ezetimibe, combination with a PCSK9 inhibitor is recommended" [13]. This recommendation carries a Class I, Level A designation and applies to all available PCSK9-targeted therapies, though inclisiran was not yet approved when the guideline was published.

The clinically meaningful differentiator is dosing frequency, not efficacy magnitude. Twice-yearly injections versus every-two-week or monthly injections represents a 12-fold to 24-fold reduction in injection frequency. Whether that difference translates into better cardiovascular outcomes through improved adherence remains to be established by ORION-4.

The Cardiovascular Outcomes Question: ORION-4

No PCSK9 siRNA therapy has yet demonstrated a reduction in major adverse cardiovascular events (MACE) in a completed outcomes trial. This is a meaningful gap. Evolocumab demonstrated a 15% relative risk reduction in MACE in the FOURIER trial (N=27,564; HR 0.85 to 95% CI 0.79-0.92; P<0.001) [14]. Alirocumab showed a similar 15% reduction in ODYSSEY OUTCOMES (N=18,924; HR 0.85 to 95% CI 0.78-0.93; P<0.001) [15].

ORION-4 is a randomized, double-blind, placebo-controlled cardiovascular outcomes trial that has enrolled approximately 15,000 patients with pre-existing ASCVD [16]. The trial is being conducted by the Clinical Trial Service Unit at the University of Oxford. Results are expected to report in 2026. Until those data are available, the assumption that LDL-C lowering with inclisiran reduces cardiovascular events rests on the established causal relationship between LDL-C and ASCVD risk, supported by Mendelian randomization studies and the consistency of benefit across statins, ezetimibe, and PCSK9 monoclonal antibodies [14][15].

For FH patients specifically, this evidence gap matters. FH confers a cumulative LDL-C burden from birth, and the absolute cardiovascular risk reduction from any LDL-lowering therapy is higher in FH than in acquired hypercholesterolemia [8]. Clinicians are making a reasonable extrapolation when prescribing inclisiran for FH based on LDL-C reduction data, but the direct MACE evidence is not yet available for this specific drug.

Practical Prescribing Considerations for FH Patients

Inclisiran 284 mg is administered as a subcutaneous injection by a healthcare provider. The loading schedule is day 1, day 90, then every six months [5]. Patients do not self-inject. This model requires that FH patients attend scheduled office visits, which can be an advantage (guaranteed administration) or a barrier (access, travel, scheduling) depending on the patient's circumstances.

Prior authorization is required by most U.S. commercial payers. Documentation typically needed includes genetic or clinical confirmation of FH diagnosis, evidence of maximally tolerated statin therapy, current LDL-C level, and prior use of ezetimibe [5]. The wholesale acquisition cost of inclisiran is approximately $3,250 per injection, or $6,500 per year at maintenance dosing. Novartis offers a patient assistance program for eligible uninsured and underinsured patients.

No dose adjustment is required for mild to moderate hepatic impairment (Child-Pugh A or B) or any degree of renal impairment, including patients on dialysis [5]. Inclisiran has not been studied in severe hepatic impairment (Child-Pugh C). Drug interactions are minimal because siRNAs are not metabolized by cytochrome P450 enzymes.

Monitoring after initiation should include a lipid panel at the 90-day visit (before the second loading dose) and again at 6 months. If LDL-C reduction is less than expected, verify adherence to background statin and ezetimibe therapy before attributing inadequate response to inclisiran itself.

Where FH Guidelines Position PCSK9-Targeted Therapy

The 2022 consensus statement from the European Atherosclerosis Society on HoFH management recommends that "all available LDL-lowering therapies, including PCSK9 inhibitors, should be considered in HoFH patients with residual LDLR activity" [17]. This recommendation encompasses inclisiran, though it notes the more limited evidence base compared to evolocumab in this population.

For HeFH, the treatment algorithm is more established. The National Lipid Association (NLA) 2023 recommendations place PCSK9-targeted therapy after maximally tolerated statin plus ezetimibe for patients who remain above their LDL-C treatment threshold [18]. The NLA does not preferentially recommend one PCSK9-targeted agent over another, leaving the choice between inclisiran, evolocumab, and alirocumab to clinician-patient shared decision-making based on dosing preference, cost, and access.

The International FH Foundation recommends cascade screening of first-degree relatives when an FH index case is identified, and early initiation of intensive lipid-lowering therapy for confirmed cases [8]. Starting PCSK9-targeted therapy earlier in the disease course, before decades of cumulative LDL-C exposure, is an area of active investigation. Pediatric trials of inclisiran are underway but have not reported results.